Clearmind Medicine Inc. Common Shares (CMND)
CMND trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | CMND on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Canada |
| IPO year | Not reported by the screener |
| SEC CIK | 0001892500 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | Canada |
Financials
Foreign filer: no machine-readable annual figure in SEC data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These factors raise substantial doubt on the Company's ability to continue as a going concern." | 20-F 2026-01-20 |
| Cash and burn | $3.9M cash; operating cash flow -$1.2M a quarter. | Report 2025-10-31 |
| Shares outstanding | No cover-page share count in XBRL | Cover page 2026-01-19 |
| Reverse splits, 3 years | 4; latest 1-for-8 on 2026-10-05 | Source 2026-10-05 |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 4 424B5 takedowns, 4 at the market | Latest 2025-12-03 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Brightman Almagor Zohar & Co., Tel Aviv, Israel | PCAOB Form AP 2026-02-23 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $91K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-10-31 | Not filed | -$3.9M | -$4.7M | $3.9M | No debt tags | Needs four quarters | 20-F 2026-01-20 |
| FY 2024 2024-10-31 | Not filed | -$5.3M | -$4.9M | $6.6M | No debt tags | Needs four quarters | 20-F 2026-01-20 |
| FY 2023 2023-10-31 | Not filed | -$8.6M | -$6.3M | $5.4M | No debt tags | Needs four quarters | 20-F 2026-01-20 |
| FY 2022 2022-10-31 | Not filed | -$6.9M | -$3.7M | $129K | No debt tags | Needs four quarters | 20-F 2025-01-22 |
| FY 2021 2021-10-31 | Not filed | -$2.7M | -$2.1M | $3.4M | No debt tags | Needs four quarters | 20-F/A 2024-03-18 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document POST-EFFECTIVE AMENDMENT NO. 3 TO FORM F-1 | POS AM | 2026-06-15 |
| Latest annual report ANNUAL REPORT | 20-F | 2026-01-20 |
| Latest quarterly / interim REPORT OF FOREIGN PRIVATE ISSUER | 6-K | 2026-11-16 |
Source: SEC EDGAR submissions feed, 375 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -18.9% |
| 1 month | -27.3% |
| 3 months | -69.4% |
| Year to date | -96.9% |
| 1 year | -99.6% |
| From 52-week high | -99.5% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| SBFM | Sunshine Biopharma Inc. | $2.60 | -3.70% | $2.1M |
| DCOY | Decoy Therapeutics Inc. | $0.9010 | -7.61% | $2.1M |
| JUNS | Jupiter Neurosciences Inc. | $1.70 | -8.11% | $2.2M |
| PPCB | Propanc Biopharma Inc. | $1.89 | -2.62% | $2.0M |
| ONCO | Onconetix Inc. | $2.91 | -9.35% | $1.9M |
| XRTX | XORTX Therapeutics Inc. Common Shares | $1.04 | -5.45% | $1.9M |
| PRFX | PRF Technologies Ltd. | $0.6948 | -11.22% | $2.4M |
| HCWB | HCW Biologics Inc. | $0.8000 | +3.48% | $1.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier